MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development

Size: px
Start display at page:

Download "MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development"

Transcription

1 MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development Danielle K Lewis, PhD April 28, 2017

2 One-Stop Shop Regulatory Submissions Regulatory Operations Regulatory Affairs Medical Writing & Disclosure Services Clinical Programming Biostatistics Data Management Medical Information Drug Safety & PV Clinical Development Support Data Abstraction GMP & GLP Services 2

3 Objectives Definition/Description of Medical Writing Drug Approval Process Discuss How the Documents We Write Fit into This Process Transitioning from Academia to Med Writing Tips and Tricks to Get That First Look 3

4 Medical Writing The art of communicating clinical and scientific data and information different from manuscript writing Communicates the effects of treatments/medications (interventions) on human subjects during clinical studies. Describes non-interventional (epidemiology, methodology, longitudinal etc.) study events and results in clinical study reports (CSRs). It also communicates the risk of a drug as well as the company plan for monitoring and negating those risks. 4

5 It is Global 5

6 Medical writing We submit documents all over the globe (eg, US, EU, Japan, Russia, Jordan, Brazil, Colombia, Mexico, South Africa, Thailand, Taiwan, Vietnam, ) 6

7 Medical Writing An ideal medical document/presentation is prepared with the audience in mind. The audience might be: A clinical/scientific team A government agency (FDA, EMA, PMDA) An objective 3 rd party reviewer/expert in the field A product consumer/public A well-written document will accurately present the information and successfully communicate the outcome in the most concise manner possible. 7

8 Medical Writing Questions medical writers ask about the documents they are writing: What is its purpose? Who is the target audience? What type of publication is it? Does a template exist? Are there previous similar documents that can be used as a guide? What are the proposed start and finish dates? Is there a specific style guideline/format that should be followed? Who will sign off on the document and at what stages? 8

9 Types of Documents Written by MMS Regulatory /Clinical Investigational new drug (IND) Clinical study protocol Case report form (CRF) Clinical study report (CSR) Common technical document (CTD) New drug application (NDA) Marketing authorization application (MAA) Summary of clinical efficacy (SCE) Summary of clinical safety (SCS) Orphan drug application Investigator s brochure (IB) update Briefing book/package Regulatory response Global feasibility document Risk management plan (RMP) Lay Summaries Marketing Academy of Managed Care Pharmacy (AMCP) dossier Medical slide deck Educational Medical training document Competitive intelligence Abstract Manuscript Poster 9

10 Drug Approval Process: Timeline, Documents Pre- Clinical Phase 1 Phase 2 Phase 3 Phase 4 Pre-IND Mtg IND Filing End of Ph2 Mtg Pre-licensing Mtg Approval NDA Filing Briefing Document IND IB CSRs Study documents: protocol; SAP; CRFs; table requirements) Briefing Document Briefing Document CTD Query Response PSURs (updated every 6 months) Annual Updates to IND, IB 10

11 Drug Approval Process: Clinical Trials Types of Clinical Trials in Humans Phase I: Try to determine dosing, document how a drug is metabolized and excreted, and identify acute side effects. Subjects: usually between 20 and 80 healthy volunteers Phase 2: Gather further safety data and preliminary evidence of the drug's beneficial effects (efficacy), and develop and refine research methods for future trials with this drug. Subjects: approximately people who have the disease or condition that the product potentially could treat. Phase 3: Further test the product's effectiveness, monitor side effects, and, in some cases, compare the product's effects to a standard treatment, if one is already available. Subjects: approximately 1,000-3,000 people with the disease. These studies also help define the safety profile of the drug 11

12 Drug Approval Process: Timeline, Documents Pre- Clinical Phase 1 Phase 2 Phase 3 Phase 4 Pre-IND Mtg IND Filing End of Ph2 Mtg Pre-licensing Mtg Approval NDA Filing Briefing Document IND IB CSRs Study documents: protocol; SAP; CRFs; table requirements and RMPs (for EMA) Briefing Document Briefing Document CTD Query Response PSURs (updated every 6 months) Annual Updates to IND, IB 12

13 Application for marketing authorization 13

14 Drug Approval Process: Timeline, Documents Pre- Clinical Phase 1 Phase 2 Phase 3 Phase 4 Pre-IND Mtg IND Filing End of Ph2 Mtg Pre-licensing Mtg Approval NDA Filing Briefing Document IND IB CSRs Study documents: protocol; SAP; CRFs; table requirements and RMPs (for EMA) Briefing Document Briefing Document CTD Query Response PSURs (updated every 6 months) Annual Updates to IND, IB 14

15 OK so what do you DO as a medical writer????? Writing Client interaction Manage timelines Set meetings up with client, go over client/writer expectations Usually work within a document management system of the client Interact with teams of 4 to 15 people and incorporate comments from said team. s, phone calls, SOP driven there is a defined process for everything 15

16 How do you transition from academia? My personal experience PhD Neuroscience Over 15 years of research Laboratory Skill Set Animal care surgery Had multiple projects to manage Wrote SOP and animals use protocols for lab Worked by myself for HOURS Wrote papers Lectured Team driven science 16

17 Come up with a new brand for yourself Laboratory Skill Set Animal care surgery - Had multiple projects to manage Wrote SOP and animals use protocols for lab Worked by myself for HOURS Had published scientific manuscripts Lectured Team-driven science Medical Writing Skill Set Ability to manage multiple timelines Writing skills Work independently Writing skills Can communicate effectively with people Ability to work in a team environment 17

18 How do you transition into Medical Writing? Write, write, write Informational interviews..network Publications, SOPs, laboratory safety, animal use protocols, grant writing Online sources: Upwork, The HittList, American Medical Writers Association Internships Showcase your skills Management and organizational skill set Teaching experience translates to ability to communicate effectively Meeting deadlines medical writing is driven by timelines 18

19 Pros and Cons of Medical Writing Pros Can do your job anywhere with secure wifi The documents are fun and interesting Job outlook is great Sense of accomplishment Cons Can do your job anywhere with secure wifi Teams can be difficult Spend a lot of time sitting 19

20 MMS Holdings Inc. MMS is a clinical research organization (CRO) based in Canton, MI. Worldwide presence (India, Europe, Japan, China, Middle East, South Africa) MMS is a growing company More than 20 new clients in new medical writers were hired at US and EU sites in

21 MMS Work Environment Professional colleagues On-site training Benefits: PTO, 401K with Employer Match, Life/Health Insurance, Flex Accounts, On-site Yoga and Chair Massages, Company Events 21

22 Questions? 22

23 Contact information Danielle K Lewis lewisdani67@gmail.com 23

24 Thank You! For additional information or questions regarding our services, visit our website: or Contact MMS: Scan with your smartphone or tablet to go to our website for more details. 24

25 Revision History Date Reason(s) Author(s) 06/13/2013 Original Philip Jessmon 02/12/2015 Updated for outreach opportunities 02/22/2017 Updated for Professional Development Series at UT/ new slide deck 04/28/2017 Updated for Texas A & M Career Development for the Biomedical PhD Scientist Lecture Teresa Cesena Jean Overmeyer Danielle Lewis 25

Japanese submission/approval from programming perspective

Japanese submission/approval from programming perspective Paper RG03 submission/approval from programming perspective Ryan Hara, Novartis, Basel, Switzerland The opinions expressed in this presentation and on the following slides are solely those of the presenter

More information

STRATEGIC RESOURCING. inventivhealthclinical.com

STRATEGIC RESOURCING. inventivhealthclinical.com STRATEGIC RESOURCING inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 STAFFING 03 MOVING UP THE VALUE CHAIN 04 FUNCTIONAL EXPERTISE Biostatistics and Statistical Programming 05 Clinical Monitoring

More information

Senior Regulatory Affairs Executive AREAS OF EXPERTISE

Senior Regulatory Affairs Executive AREAS OF EXPERTISE Senior Regulatory Affairs Executive AREAS OF EXPERTISE More than fifteen years experience in vaccines, pharmaceuticals, biotechnology, and combination device products. Experience in regulatory strategy

More information

Drug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018

Drug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018 Drug Registration in BRICS countries: Opportunities and Challenges Judith ter Horst 1 November 2018 Once a drug reaches Phase1, it s a good idea to start discussions with global regulatory authorities

More information

MEDICAL WRITING. Zhiyun Lynn Guan Medical Writer, Medtronic April 9, 2018

MEDICAL WRITING. Zhiyun Lynn Guan Medical Writer, Medtronic April 9, 2018 MEDICAL WRITING NEW CHALLENGES AND OPPORTUNITIES Zhiyun Lynn Guan Medical Writer, Medtronic April 9, 2018 Disclaimer The views in this presentation are my own, and do not represent those of Medtronic or

More information

PharmaSUG 2012 Paper #IB01

PharmaSUG 2012 Paper #IB01 PharmaSUG 2012 Paper #IB01 Adapt and Survive: Implementing the new ICH Development Safety Update Report (DSUR) Patricia L. Gerend, Genentech Inc., South San Francisco, CA Rajkumar Sharma, Genentech Inc.,

More information

Ensuring Quality of Regulatory Clinical Documents

Ensuring Quality of Regulatory Clinical Documents Ensuring Quality of Regulatory Clinical Documents Henry Li *, Kim Hanna and Steve Petteway Talecris Biotherapeutics, Research Triangle Park, North Carolina, USA Summary A large number of clinical documents

More information

RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018

RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018 1 RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018 Doreen W Lechner, PhD Program Director, MS Clinical Trial Sciences Program Biopharma Educational Initiative Rutgers School of Health Professions

More information

Academia to Industry and Back

Academia to Industry and Back Academia to Industry and Back TRENT WATKINS, PH.D. ASSISTANT PROF., DEPT. OF NEUROSURGERY BAYLOR COLLEGE OF MEDICINE My winding career path Stanford: Ph.D. in Neuroscience Genentech: An academic research

More information

Emerging Trends in Regulatory Outsourcing WHITE PAPER.

Emerging Trends in Regulatory Outsourcing WHITE PAPER. WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a

More information

Regulatory progress for innovation/international trend on pharmaceutical regulatory convergence Introduction of Horizon Scanning in ICMRA

Regulatory progress for innovation/international trend on pharmaceutical regulatory convergence Introduction of Horizon Scanning in ICMRA Regulatory progress for innovation/international trend on pharmaceutical regulatory convergence Introduction of Horizon Scanning in ICMRA 6 th Joint Conference of Japan and Taiwan on Medical Products Regulation

More information

The Role of the Writer in Regulatory Affairs. Julie Bowdler 19 May 2014

The Role of the Writer in Regulatory Affairs. Julie Bowdler 19 May 2014 The Role of the Writer in Regulatory Affairs Julie Bowdler 19 May 2014 How I became a regulatory writer Degree in Biochemistry DPhil in Neuropharmacology Medical publishing and conference organization

More information

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program

More information

CONTRACT RESEARCH SERVICES

CONTRACT RESEARCH SERVICES 1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply

More information

May 9, Creating a Successful Global Value Dossier

May 9, Creating a Successful Global Value Dossier May 9, 2018 Creating a Successful Global Value Dossier Anne Heyes Head Market Access and Outcomes Strategy (Europe) Stephanie Barrows Senior Director Market Access and Outcomes Strategy Caroline Ling Senior

More information

Drug Development Services

Drug Development Services Drug Development Services Speaker Introduction Nik Burlew Vice President Regulatory and Strategic Development 25 Years in Pharma: Development, MFG and QA. Consulting for the last 13 years primarily to

More information

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS

More information

Simplifying Clinical Trials

Simplifying Clinical Trials Simplifying Clinical Trials A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. Company Overview : PPCE is an efficient

More information

Clinical Data Management Services

Clinical Data Management Services Clinsoft Overview Clinical Trial Management Clinical Data Management Services Medical Writing & Pharmacovigilance Services 2 Overview Started in 2008 with a small group of 7 team members. Expanded to a

More information

Cardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences

Cardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences Cardinal Health Specialty Solutions Bringing a new drug to life Regulatory Sciences How we guided a pharma s breakthrough vision to commercial reality The right drug can mean the difference between life

More information

Introduction to CMC Regulatory Affairs

Introduction to CMC Regulatory Affairs Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4

More information

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS How TOPRA can support you as you drive your regulatory career forward ABOUT TOPRA TOPRA (The Organisation for Professionals in Regulatory Affairs)

More information

Regulatory requirements and registration process of Generic Drugs in China

Regulatory requirements and registration process of Generic Drugs in China 13 Regulatory requirements and registration process of Generic Drugs in China Jitendra Kumar Badjatya Deputy Manager-DRA, Montajat Pharmaceutical Company Limited, Dammam, KSA jeetbadjatya@gmail.com ABSTRACT

More information

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40

More information

University of Pennsylvania Biomedical and Life Sciences Career Fair

University of Pennsylvania Biomedical and Life Sciences Career Fair University of Pennsylvania Biomedical and Life Sciences Career Fair Pooja Talati, PhD, Senior Medical Writer Danielle Love, Associate Vice President, Group Account Supervisor Brendon Phalen, MD, MBA, Managing

More information

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical

More information

Envigo Corporate & Industry Overview. Rutgers University

Envigo Corporate & Industry Overview. Rutgers University Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research

More information

Regulatory Updates in Taiwan

Regulatory Updates in Taiwan 6th Joint Conference of Taiwan and Japan on Medical Products Regulation Regulatory Updates in Taiwan Shou-Mei Wu, Taiwan Food and Drug Administration Oct. 11, 2018 Outlines 01 02 03 04 05 06 Mission, Vision,

More information

HUMAN CHALLENGE TESTING

HUMAN CHALLENGE TESTING HUMAN CHALLENGE TESTING CLINICAL RESEARCH SOLUTIONS DE-RISKING Faced with increasing pressures on timelines and budgets, clinical research practices need to continuously evolve in order to ensure pipeline

More information

Impact of MRCT after ICH E17 fully implement -Industry perspective-

Impact of MRCT after ICH E17 fully implement -Industry perspective- Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation

More information

DIFFERING CMC REQUIREMENTS: US AND EU

DIFFERING CMC REQUIREMENTS: US AND EU WHITEPAPER DIFFERING CMC REQUIREMENTS: US AND EU Torsten Schnetgoeke M.Sc. Senior Manager, Regulatory Affairs torsten.schnetgoeke@pharmalex.com Torsten joined PharmaLex in 2015 as a Senior Manager in Regulatory

More information

Planning of Application

Planning of Application 2016 Good Registration Management Regulatory Science Center of Excellence Pilot Workshop Planning of Application Moderator: Speaker: Jin Shun, AbbVie Thean Soo Lo, J&J Sannie Chong, Roche Agenda 10:00~10:05

More information

BIOMETRICS SERVICES ADVISORY DATA OFFICE UNBLINDING SECURE INDEPENDENT TEAM PROGRAM. ADaM TRAINER SAFETY SDTM COMPLIANT TA-EXPERTISE SDTM DATA

BIOMETRICS SERVICES ADVISORY DATA OFFICE UNBLINDING SECURE INDEPENDENT TEAM PROGRAM. ADaM TRAINER SAFETY SDTM COMPLIANT TA-EXPERTISE SDTM DATA BIOMETRICS SERVICES DELIVER UNBLINDED DATASETS TO IDMC SDTM-IG UNBLINDING ADVISORY QUALITY ON TIME DEDICATED DATA SECURE BOARD EMERGENCY PARTNERSHIPTEAM DATA OFFICE UNBLINDING INVESTINGEXPERTISE SHARING

More information

Your Complete Quality Solution Provider for the Life Science Industry

Your Complete Quality Solution Provider for the Life Science Industry Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,

More information

Global Development of Drugs and Co-operation among Asian Economies

Global Development of Drugs and Co-operation among Asian Economies Global Development of Drugs and Co-operation among Asian Economies Chi-Chou Liao, Ph.D. Director General Bureau of Pharmaceutical Affairs, Department of Health, Chinese Taipei 2006 Symposium on Asia Pacific

More information

An Introduction to Clinical Research and Development

An Introduction to Clinical Research and Development Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is

More information

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE

More information

Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective. Brian K. Nunnally, Ph.D.

Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective. Brian K. Nunnally, Ph.D. Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective Brian K. Nunnally, Ph.D. Agenda The Lifecycle Approach a guidance review What it really means Global Emerging Markets and

More information

(Historic Developments Undertaken by CFDA)

(Historic Developments Undertaken by CFDA) Review Impact of Emerging CFDA (China FDA) Guidelines/Standards (Historic Developments Undertaken by CFDA) Qiang Zheng Peking University, Beijing China IPAC-RS/RDD 2016 Symposium Scottsdale 2016-4-22 Timeline

More information

University joins Industry: Clinical Trials & Drug Safety. Aula Magna-Facultad de Farmacia 11 Marzo 2015

University joins Industry: Clinical Trials & Drug Safety. Aula Magna-Facultad de Farmacia 11 Marzo 2015 University joins Industry: Clinical Trials & Drug Safety Aula Magna-Facultad de Farmacia 11 Marzo 2015 Contents Background, key points and basic knowledge Department tasks and responsibilities Importance

More information

Our story. Today we serve our clients with pride, agility & compliance with the professionalism that they seek for.

Our story. Today we serve our clients with pride, agility & compliance with the professionalism that they seek for. COMPANY PROFILE Our story From what we experienced in the need within the Saudi & GCC market for vendors who could be a solution provider in the Pharmaceutical field, we ELMAQ team have joined up from

More information

We set things in motion and keep them moving. Metronomia Clinical Research Services

We set things in motion and keep them moving. Metronomia Clinical Research Services We set things in motion and keep them moving Metronomia Clinical Research Services Our customers love the fact that we keep up with their individual tempos. Dorothea Wessiepe, Director Biostatistics Metronomia:

More information

Medical Information Role in the Pharmaceutical Industry

Medical Information Role in the Pharmaceutical Industry www.arisglobal.com A White Paper Presented By ArisGlobal Medical Information Role in the Pharmaceutical Industry by Ome Ogbru, PharmD, SME, Medical Communications & Sanjay Kumar D, Product Marketing Manager

More information

Clinical Trials A Closer Look

Clinical Trials A Closer Look The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription and over-the counter) Food Medical devices Animal feed and drugs Cosmetics

More information

The Investigator s Brochure: A multidisciplinary document

The Investigator s Brochure: A multidisciplinary document The Investigator s Brochure: A multidisciplinary document Douglas Fiebig Trilogy Writing & Consulting GmbH, Frankfurt am Main, Germany Correspondence to: Douglas Fiebig Trilogy Writing & Consulting GmbH,

More information

Overview of global registration of vaccines

Overview of global registration of vaccines Overview of global registration of vaccines by Dr. Nora Dellepiane Workshop: Global Registration and Vaccine Shortage Taipei, Taiwan 6 to 10 March 2017 Outline of the presentation The objective of medicines

More information

Considerations for Global Development of Orphan Drugs. Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc.

Considerations for Global Development of Orphan Drugs. Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc. Considerations for Global Development of Orphan Drugs Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc. 1 Disclosures Shareholder No Grant/research support No Consultant

More information

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn

More information

OCTC 2012 CRO Selection

OCTC 2012 CRO Selection OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed

More information

Trends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference

Trends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference Trends in pharmacovigilance inspection deviations 8th Scandinavian SARQA/DKG Quality Assurance Conference Thorsten Jørgensen, PV Auditor, LEO Global Quality 1 Disclaimer This presentation does not represent

More information

Impact factor: 3.958/ICV: 4.10 ISSN:

Impact factor: 3.958/ICV: 4.10 ISSN: Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 514 Pharma Science Monitor 8(2), Apr-Jun 2017 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com

More information

Career in Biotechnology Industry. Novartis Biocamp Roadshow

Career in Biotechnology Industry. Novartis Biocamp Roadshow Career in Biotechnology Industry Novartis Biocamp Roadshow What is biotechnology? Biotechnology, often referred to as biotech, is the application of biological research techniques to create new processes

More information

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective ISPE Japan Affiliate 2016 Annual Meeting, April 14-15, 2016, Tower hall Funabori, Tokyo, Japan ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal

More information

The Hiring Process in Academia. Will focus primarily on tenure-track process

The Hiring Process in Academia. Will focus primarily on tenure-track process The Hiring Process in Academia Will focus primarily on tenure-track process Hiring process Differs between departments: committees make shortlists faculty often votes to rank-order shortlists administration

More information

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following

More information

Regulations of Biologics in Taiwan

Regulations of Biologics in Taiwan Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including

More information

Pre-consultation system at the authority for clinical trials and NDA in Japan

Pre-consultation system at the authority for clinical trials and NDA in Japan Pharmaceuticals and Medical Devices Agency Pre-consultation system at the authority for clinical trials and NDA in Japan Takeyuki SATO Associate Director, Centre for Product Evaluation Pharmaceuticals

More information

GLOBAL Trend and opportunities in drug development

GLOBAL Trend and opportunities in drug development GLOBAL Trend and opportunities in drug development พญ อรณ ต งเผ า Oranee T Daniels MD October 2015 Looking back during last 15 years Drug safety became a focus for both regulators and drug developers.

More information

Investigational New Drug Application

Investigational New Drug Application Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution

More information

Syllabus for M.Pharm Clinical Research Semester II

Syllabus for M.Pharm Clinical Research Semester II Syllabus for M.Pharm Clinical Research Semester II Clinical Research Methodology Paper I MPCR 201 T Scope After Completion of the course students should be able to understand various practical aspects

More information

Analyze Samples: Job Posting and Resumes Overview

Analyze Samples: Job Posting and Resumes Overview Analyze Samples: Job Posting and Resumes Overview Alberta Government job postings provide information about the job, work environment, and the qualifications needed for successful performance (education,

More information

Document Reuse: Theory and Practice

Document Reuse: Theory and Practice Document Reuse: Theory and Practice Peggy Boe, RN Sr. Director, Medical Writing Image Solutions, Inc (ISI) Company logo here Best Practice: Single Sourcing Creating reusable text and information Requires

More information

US FDA and International Regulatory Efforts in Cellular and Gene Therapies

US FDA and International Regulatory Efforts in Cellular and Gene Therapies US FDA and International Regulatory Efforts in Cellular and Gene Therapies ISCT Satellite Global Regulatory Perspectives Workshop January 27, 2013 Kimberly Benton, Ph.D. Deputy Director, Division of Cellular

More information

PhUSE Single Day Event 2009, Frankfurt

PhUSE Single Day Event 2009, Frankfurt Risk Based Approach Applied to the Validation of Report Objects PhUSE Single Day Event 2009, Frankfurt Christoph Ziegler, F. Hoffmann La Roche AG, Basel, Switzerland Agenda Introduction Definition of Risk

More information

The Practical Application of Regulatory Science

The Practical Application of Regulatory Science TOPRA Annual Human Medicines Symposium 2017 The Practical Application of Regulatory Science Impact on Regulatory Policy and Practice Lawrence Liberti, PhD, RAC, RPh Executive Director ENABLING AND PROMOTING

More information

Optimize Your Medical Affairs Team s Influence in a Start-up Organization

Optimize Your Medical Affairs Team s Influence in a Start-up Organization Optimize Your Medical Affairs Team s Influence in a Start-up Organization Rachel Couchenour, PharmD, MBA Sr. Director, Medical Affairs Mateon Therapeutics Objectives Discover the unique challenges faced

More information

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,

More information

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services Welcome Thank you for joining us Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services 360 o SERVICE PERFORMANCE MEASUREMENT Sponsor View TM 5 Assessments Available

More information

Your bridge to. better medicines

Your bridge to. better medicines Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)

More information

NUVISAN GROUP. Our Philosophy

NUVISAN GROUP. Our Philosophy NUVISAN GROUP Our Philosophy 2 EARLY DEVELOPMENT Introduction to Nuvisan Fully integrated Contract Research Organisation headquarted in Neu-Ulm, southern part of Germany. Nuvisan - Early Development Headquartered

More information

Continuous Manufacturing PMDA s Perspective

Continuous Manufacturing PMDA s Perspective Continuous Manufacturing PMDA s Perspective Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) Sep 27, 2016 ISCMP 1 A Background ICH(1) One of the

More information

The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas. Investigator Initiated Trial (IIT) Future for IIT from the past experience

The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas. Investigator Initiated Trial (IIT) Future for IIT from the past experience The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas Investigator Initiated Trial (IIT) Future for IIT from the past experience JMACCT Project Clinical Trial Research Project of JMACCT

More information

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities Nuvisan Presentation Outsourcing and Clinical Trials DACH, 9th October 2018 Finding the right partner for preclinical into phase I Facts, Threats & Opportunities 9 October 2018 1 PASSIONATE PEOPLE FOR

More information

Sponsoring an IND? Ignorance is Not Always Blissful

Sponsoring an IND? Ignorance is Not Always Blissful Translational Science 2013 Navigating The FDA Regulatory Landscape April 19, 2013 Washington D.C. Sponsoring an IND? Ignorance is Not Always Blissful Lisa A. Speicher, Ph.D Director, Clinical Trials Office

More information

A drug development crossroad lies ahead

A drug development crossroad lies ahead G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A

More information

NON-FDA INVESTIGATOR-INITIATED PROTOCOL TEMPLATE

NON-FDA INVESTIGATOR-INITIATED PROTOCOL TEMPLATE NON-FDA REGULATED BIOMEDICAL/BEHAVIOURAL* RESEARCH PROTOCOL (*If a clinical test is performed and/or a drug is being used in the study design, follow the FDA REGULATED BIOMEDICAL RESEARCH template. Investigators

More information

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical

More information

Tier Assessment/Setting - Quick Guide to Competency Levels

Tier Assessment/Setting - Quick Guide to Competency Levels Tier Assessment/Setting - Quick Guide to Competency Levels RESEARCH OPERATIONS Competency Fundamental Skilled Advanced Interactions with IRB Candidate has used the system to successfully submit documents

More information

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical

More information

DIA Document & Records Management SIAC

DIA Document & Records Management SIAC DIA Document & Records Management SIAC EDM Reference Model Clinical Domain John Aitken, PhD Director, Regulatory Operations Gilead Sciences Inc Points to Cover Clinical Domain In scope: CTD clinical documents

More information

Putting CDISC Standards to Work How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay

Putting CDISC Standards to Work How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay Jon Roth, Vice President, Data Sciences & Biometrics Authorized Trainer for ADaM, CDISC Mark Vieder,

More information

Grindeks years of growth

Grindeks years of growth Grindeks years of growth Mission, vision and values of Grindeks Focus of Grindeks Business fields Turnover and profit TOP products of Grindeks Manufacturing value final dosage forms with high added value

More information

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Empaques Primarios y Tendencias Farmaceuticas para Inyectables 1 International Support Support in R&D Technology Transfer

More information

Advanced Therapies in Europe

Advanced Therapies in Europe Advanced Therapies in Europe 1 ATMPs in Europe (2009-2017) ~ 500 clinical trials using ATMPs in EU ~ 270 ATMP classifications 18 MAAs reviewed ~ 250 scientific advice requests 9 ATMPs approved 2 3 withdrawn

More information

PharmaSUG Paper IB15

PharmaSUG Paper IB15 PharmaSUG 2016 - Paper IB15 Importance of Niche Provider for Successful NDA Submission: Rescue Case Study Aparna Poona, Vita Data Sciences, Waltham, MA Bhavin Busa, Vita Data Sciences, Waltham, MA Tim

More information

Executive Search. Chief Standards Officer

Executive Search. Chief Standards Officer Executive Search Chief Standards Officer Client Overview Sterling Martin Associates has been retained by the Clinical Data Interchange Standards Consortium (CDISC) to search for Chief Standards Officer

More information

Evolving Regulatory Guidance on Submission of Standardized Data. James R. Johnson, PhD RTP CDISC User Network

Evolving Regulatory Guidance on Submission of Standardized Data. James R. Johnson, PhD RTP CDISC User Network Evolving Regulatory Guidance on Submission of Standardized Data James R. Johnson, PhD RTP CDISC User Network 2014-06-11 Originally Presented at PhUSE Conference 2013 Brussels, Belgium (Paper Number: RG03)

More information

CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS

CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various

More information

Some challenges in the development of new toxicity assays using in vitro methods

Some challenges in the development of new toxicity assays using in vitro methods 1 Some challenges in the development of new toxicity assays using in vitro methods J Malcolm Wilkinson, CEO, Kirkstall Ltd. Quasi Vivo - saving lives through better science The challenge: long drug development

More information

Quality Assurance in Clinical Trials

Quality Assurance in Clinical Trials Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:

More information

The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)

The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) in partnership with The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) CTRad Clinical Trials Workshop 14/10/2014 What is

More information

Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets

Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,

More information

Job Title: Head, Clinical Science Job Location: Nanjing, China CV to: Wechat:

Job Title: Head, Clinical Science Job Location: Nanjing, China  CV to: Wechat: Job Title: Head, Clinical Science Job Description: As a senior member of the Clinical Development organization, the Head of Clinical Science will supervise a team of staff to lead the clinical development

More information

elearning Catalog DIAglobal.org/eLearning

elearning Catalog DIAglobal.org/eLearning elearning Catalog DIAglobal.org/eLearning Continuing education DIA s Continuing education program has been approved by a wide range of leading accrediting bodies that oversee the awarding of continuing

More information

Corporate Presentation. October 2017

Corporate Presentation. October 2017 Corporate Presentation October 2017 Company Overview OPIS is an international CRO providing: - A wide range of clinical and e-clinical services for Pharmaceutical and Biotechnology Industries, Medical

More information

KINGSMANN CARE GROUP

KINGSMANN CARE GROUP PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting

More information

Sandoz Talent Excellence Program. Shaping the future of healthcare. Program Overview. Published on Sandoz US (

Sandoz Talent Excellence Program. Shaping the future of healthcare. Program Overview. Published on Sandoz US ( Published on Sandoz US (https://www.us.sandoz.com) Home > Printer-friendly PDF > Sandoz Talent Excellence Program Sandoz Talent Excellence Program Shaping the future of healthcare The Sandoz Talent Excellence

More information

Ensuring patient safety and regulatory compliance in an era of ever expanding complexity: Key considerations for today s pharmacovigilance leader

Ensuring patient safety and regulatory compliance in an era of ever expanding complexity: Key considerations for today s pharmacovigilance leader FOR PHARMA & LIFE SCIENCES WHITE PAPER Ensuring patient safety and regulatory compliance in an era of ever expanding complexity: Key considerations for today s pharmacovigilance leader SUMMARY There is

More information

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements

More information

Global Clinical Trials in Korea

Global Clinical Trials in Korea Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials

More information